Holdings
25
Concentrated
Top 10 weight
62%
Concentration
Active share
-
Style
Equity
95%
Asset allocation
Portfolio
-Sectors
9High-conviction bets
-Top sector wt.
0.0%Cash
Market-cap allocation
Large cap33%
Mid cap31%
Small cap31%
Asset allocation
Equity95%
Top holdings
10.6%
Divi's Laboratories Ltd.EQUITY
7.2%6.8%
6.6%
5.7%
5.6%
Aurobindo Pharma Ltd.EQUITY
5.3%TrepsCASH_EQUIVALENT
5.2%Zydus Lifesciences Ltd.EQUITY
5.1%Fortis Healthcare Ltd.EQUITY
4.5%Gland Pharma Ltd.EQUITY
3.8%Aster DM Healthcare Ltd.EQUITY
3.2%Global Health Ltd.EQUITY
3.2%IPCA Laboratories Ltd.EQUITY
3.1%Biocon Ltd.EQUITY
2.9%2.9%
2.8%
2.7%
2.7%
Acutaas Chemicals Ltd.EQUITY
2.4%Mankind Pharma Ltd.EQUITY
2.4%Anthem Biosciences Ltd.EQUITY
2.1%2.1%
2.1%
Net Receivables / (Payables)CASH_EQUIVALENT
-0.4%AI Smart summary
Pros
- Balanced across the metrics we track.
Cons
- Compact 25-stock portfolio - higher single-stock impact.
- High top-10 concentration (62%).
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in this category.
No peers found in this category.
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
62.5%
27.1%
5.6%